@article{0170f3be3457494aab68f8eb3cd6ea90,
title = "In honor of Professor Robert P. Hanzlik on the occasion of his retirement",
author = "Wang, {Siming L.} and Longqin Hu and Binghe Wang",
note = "Funding Information: Professor Hanzlik{\textquoteright}s research has embraced organic chemistry, enzyme inhibition, drug metabolism and toxicology. His interest in the latter is best described in his own words: “I look at simple chemicals that one might encounter in industry, in agriculture, in the environment, or even as drugs, and I ask the question—how do they cause toxic effects on cells?” His research has employed approaches ranging from physical organic chemistry to the use of mass spectrometry-based proteomics to characterize reactive metabolites from bromobenzene and thiobenzamide and identify their protein targets to help elucidate the contribution of covalent protein binding to toxicity. He also conducted pioneering research on electrophilic inhibitors of cysteine proteases, studied mechanisms of aliphatic and aromatic hydroxylation, discovered cyclopropylamines as suicide substrates for cytochrome P450s, and investigated the biotransformation and toxicity of transition metal organometallics such as ferrocene. Professor Hanzlik{\textquoteright}s research was supported by many sources including the NIH, the University of Kansas, NSF-NATO, The American Lung Association, Research Corporation, Ethyl Corporation, The American Heart Association, Merck Research Laboratories, Eli Lilly, and Pfizer. In his long career he has authored or co-authored 160 peer-reviewed research publications, 14 reviews, and a textbook (Inorganic Aspects of Biological and Organic Chemistry). ",
year = "2020",
month = jul,
day = "1",
doi = "10.1007/s00044-020-02584-7",
language = "English (US)",
volume = "29",
pages = "1091--1092",
journal = "Medicinal Chemistry Research",
issn = "1054-2523",
publisher = "Birkhause Boston",
number = "7",
}